SYK Inhibitor, R406

• CAT Number: I005038
• CAS Number: 841290-80-0
• Molecular Formula: C₂₂H₂₃FN₆O₅
• Molecular Weight: 470.45
• Purity: ≥95%
• Target: Spleen Tyrosine Kinase (Syk)
• Solubility: DMSO 20 mg/ml
• Storage: 3 years -20℃ powder
• IC50: 41 nM [1]
• IUPAC Name: 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
• InChI: InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
• InChIKey: NHHQJBCNYHBUSI-UHFFFAOYSA-N
• SMILES: CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C

SYK Inhibitor, R406 (Cat.No:I005038), is a small molecule inhibitor that targets spleen tyrosine kinase (SYK). It has shown efficacy in preclinical studies as an anti-inflammatory and immunosuppressive agent. R406’s ability to block SYK-mediated signaling pathways makes it a promising candidate for the treatment of autoimmune diseases and certain B-cell malignancies.

Reference

[1]. Braselmann S, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
[2]. Quiroga MP, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood, 2009, 114(5), 1029-1037.
[3]. Lhermusier T, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost, 2011, 9(10), 2067-2076.
[4]. Zhu Y, et al. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.